• 1
    Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers. Diabetes Care 2000; 23: 71175.
  • 2
    Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven GM. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 1985; 248(3 Pt 1): E28691.
  • 3
    Lillioja S, Mott DM, Zawadzki J et al. In vivo insulin action is a familial characteristic in nondiabetic Pima Indians. Diabetes 1987; 36: 132935.
  • 4
    Zoratti R, Godsland IF, Chaturvedi N, Crook D, Stevenson JC, McKeigue PM. Relation of plasma lipids to insulin resistance, nonesterified fatty acids, and body fat in men from three ethnic groups: relevance to variations in risk of diabetes and coronary artery disease. Metabolism 2000; 49: 24552.
  • 5
    Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595607.
  • 6
    Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of the diabetic parents. Ann Intern Med 1990; 113: 90912.
  • 7
    Lillioja S, Mott DM, Spraul M et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 198892.
  • 8
    Zavaroni I, Bonora E, Pagliara M et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320: 7026.
  • 9
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 53953.
  • 10
    Executive Summary of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 248697.
  • 11
    Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 105962.
  • 12
    Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 16405.
  • 13
    Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010; 375: 1813.
  • 14
    Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289304.
  • 15
    Simmons RK, Alberti KG, Gale EA et al. The metabolic syndrome; useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53: 6005.
  • 16
    Olefsky JM, Reaven GM, Farquhar JW. Effects of weight reduction on obesity: studies of carbohydrate and lipid metabolism. J Clin Invest 1974; 53: 6476.
  • 17
    Wildman RP, Munter P, Reynolds K et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Arch Intern Med 2008; 168: 161724.
  • 18
    McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004; 53: 4959.
  • 19
    Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970; 49: 215160.
  • 20
    Greenfield MS, Doberne L, Kraemer F, Tobey TA, Reaven GM. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981; 30: 38792.
  • 21
    Pei D, Jones CN, Bhargava R, Chen Y-DI, Reaven GM. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 1994; 37: 8435.
  • 22
    McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 2007; 167: 6428.
  • 23
    Abbasi F, Brown BWB, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 93743.
  • 24
    Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998; 83: 27736.
  • 25
    Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001; 86: 35748.
  • 26
    Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen R. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 426.
  • 27
    Farin HMF, Abbasi F, Reaven GM. Body mass index and waist circumference both contribute to differences in insulin-mediated glucose disposal in nondiabetic adults. Am J Clin Nutr 2006; 83: 4751.
  • 28
    Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res 2003; 11: 122331.
  • 29
    Farin HMF, Abbasi F, Reaven GM. Comparison of body mass index versus waist circumference with the metabolic changes that increase the risk of cardiovascular disease in insulin-resistant individuals. Am J Cardiol 2006; 98: 10536.
  • 30
    Lee J, Ma S, Heng D et al. Should central obesity be an optional or essential component of the metabolic syndrome? Diabetes Care 2007; 30: 3437.
  • 31
    Balkau B, Deanfield JE, Despres JP et al. International day for the evaluation of abdominal obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 1268,000 primary care patients in 63 countries. Circulation 2007; 116: 194251.
  • 32
    Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 176978.
  • 33
    Sattar N, McConnachie A, Sharper AG et al. Can metabolic syndrome predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371: 192735.
  • 34
    Cameron AJ, Magliano DJ, Zimmet PZ et al. The metabolic syndrome as a tool for predicting future diabetes. Intern Med 2008; 264: 17786.
  • 35
    Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a predictor of cardiovascular disease and type 2 diabetes. Circulation 2005; 112: 306672.
  • 36
    Eddy DM, Schlessinger L, Heikes K. The metabolic syndrome and cardiovascular risk. Implication for clinical practice. Int J Obes 2008; 32(Suppl 2): S510.
  • 37
    Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndriome improve identification of individuals ar risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 267681.
  • 38
    Stern MP, Williams K, Haffner SM. Identification of individuals at high risk of type 2 diabetes: do we ned the oral glucose tolerance test? Ann Intern Med 2002; 136: 57581.
  • 39
    McNeill AM, Rosamond WD, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 38590.
  • 40
    Wannamethee SG, Shaper AG, Lennon L, Morriss RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes. Arch lnt Med 2005; 165: 264450.
  • 41
    Facchini FS, Hollenbeck CB, Jeppesen J, Chen Y-DI, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 112830.
  • 42
    Zavaroni I, Bonini L, Gasparini P, Dall’Aglio E, Passeri M, Reaven GM. Cigarette smokers are relatively glucose intolerant, hyperinsulinemic and dyslipidemic. Am J Cardiol 1994; 73: 9045.
  • 43
    Mancia G, Bombelli M, Corrao G et al. Metabolic syndrome in the Pressioni Arteriose Monitorte E Loro Associazioni (PAMELA) Study. Daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 407.